SCHEMBL24765441

SCHEMBL24765441

CC(=O)NCCOCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ FPR3 P25089 1/20 0.38
▸ FPR2 P25090 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.37
▸ HTR4 Q13639 1/20 0.36
▸ DAO P14920 1/20 0.36
▸ MAOB P27338 3/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21106866 1.00 MEN1 (0.41) MEN1KMT2ATP53SMN1; SMN2NPSR1
SCHEMBL23945709 0.99 TP53 (0.41) MEN1KMT2ATP53SMN1; SMN2NPSR1
SCHEMBL21107592 0.87 MEN1 (0.47) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL22856287 0.87 MEN1 (0.47) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL25477805 0.86 SMN1; SMN2 (0.44) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL25913732 0.86 SMN1; SMN2 (0.44) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL21107025 0.86 MEN1 (0.45) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL25972108 0.86 TP53 (0.40) MEN1KMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL24572502 0.85 PAOX (0.44) MEN1KMT2ANPSR1ALDH1A1DRD2
SCHEMBL22909028 0.85 PAOX (0.44) MEN1KMT2ANPSR1ALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF MERTK, ITK, CRKL MEN1 1064/4885KMT2A 1096/4885TP53 508/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885TP53 1474/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885TP53 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback